4.5 Article

Bacterial Taxa and Functions Are Predictive of Sustained Remission Following Exclusive Enteral Nutrition in Pediatric Crohn's Disease

Journal

INFLAMMATORY BOWEL DISEASES
Volume 26, Issue 7, Pages 1026-1037

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izaa001

Keywords

pediatric Crohn's disease; exclusive enteral nutrition; gut microbiome; nutrition in pediatrics

Funding

  1. Canadian Institutes of Health Research (CIHR)-Canadian Association of Gastroenterology-Crohn's Colitis Canada New Investigator Award (2015-2019)
  2. Canada Research Chair Tier 2 in Translational Microbiomics (2018-2019)
  3. Canadian Foundation of Innovation John R. Evans Leadership fund [35235, 36764]
  4. Nova Scotia Health Research Foundation (NSHRF)
  5. IWK Health Centre Research Associateship
  6. Future Leaders in IBD project grant
  7. CIHR-SPOR-Chronic Diseases grant (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects: the IMAGINE-SPOR chronic disease network)
  8. American Gastroenterology Association Pfizer Young Investigator Pilot Research Award in Inflammatory Bowel Disease (2018)
  9. Weston Foundation Postbiotics grant (2019-2020)
  10. NASPGHAN/CCFA Young Investigator award 2013-2015

Ask authors/readers for more resources

Background: The gut microbiome is extensively involved in induction of remission in pediatric Crohn's disease (CD) patients by exclusive enteral nutrition (EEN). In this follow-up study of pediatric CD patients undergoing treatment with EEN, we employ machine learning models trained on baseline gut microbiome data to distinguish patients who achieved and sustained remission (SR) from those who did not achieve remission nor relapse (non-SR) by 24 weeks. Methods: A total of 139 fecal samples were obtained from 22 patients (8 15 years of age) for up to 96 weeks. Gut microbiome taxonomy was assessed by 16S rRNA gene sequencing, and functional capacity was assessed by metagenomic sequencing. We used standard metrics of diversity and taxonomy to quantify differences between SR and non-SR patients and to associate gut microbial shifts with fecal calprotectin (FCP), and disease severity as defined by weighted Pediatric Crohn's Disease Activity Index. We used microbial data sets in addition to clinical metadata in random forests (RFs) models to classify treatment response and predict FCP levels. Results: Microbial diversity did not change after EEN, but species richness was lower in low-FCP samples (<250 mu g/g). An RF model using microbial abundances, species richness, and Paris disease classification was the best at classifying treatment response (area under the curve [AUC] = 0.9). KEGG Pathways also significantly classified treatment response with the addition of the same clinical data (AUC = 0.8). Top features of the RF model are consistent with previously identified IBD taxa, such as Ruminococcaceae and Ruminococcus gnavus. Conclusions: Our machine learning approach is able to distinguish SR and non-SR samples using baseline microbiome and clinical data.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available